A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients.
Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM.
Jenum S, et al. Among authors: mortensen r.
Nat Commun. 2021 Nov 22;12(1):6774. doi: 10.1038/s41467-021-27029-6.
Nat Commun. 2021.
PMID: 34811370
Free PMC article.
Clinical Trial.